MAPT and Alzheimer disease: In in vivo studies, conducted, among others, on 3xTg-AD transgenic mice, oral administration of sulforaphane at doses of 10–50 mg/kg for 8 weeks resulted in a significant reduction in the levels of Aβ amyloid and tau protein and its phosphorylated forms.